<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>VIVUS' (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript | Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />
<script type="text/javascript" src="http://static.cdn-seekingalpha.com/javascripts/rollbar.js?3"></script>
<script type="text/javascript" src="http://static.cdn-seekingalpha.com/javascripts/ie_jump_list.js"></script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Breaking News - Real-time stock market news updates ;action-uri=http://seekingalpha.com/news/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta property="fb:admins" content="100006791796236" />

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="VIVUS' (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript">
<meta name="twitter:description" content="VIVUS, Inc. (NASDAQ:VVUS) Q3 2014 Earnings Conference Call November 5, 2014 4:30 PM ET 
  Executives
 Dana Shinbaum - Corporate Development and IR Svai Sanford - Interim CFO Seth Fischer - CEO 
  Analysts">
<meta name='twitter:image' content='http://static1.cdn-seekingalpha.com/images/users_profile/000/101/639/big_pic.png?1361390225'><link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="description" content="VIVUS, Inc. (NASDAQ:VVUS) Q3 2014 Earnings Conference Call November 5, 2014 4:30 PM ET Executives Dana Shinbaum - Corporate Development and IR Svai Sanford -" /><meta name="keywords" content="NASDAQ:VVUS" /><meta name="news_keywords" content="VVUS, Vivus Inc., Healthcare, Transcripts, United States, Biotechnology" /><link rel="alternate" media="only screen and (max-width: 640px)" href="http://m.seekingalpha.com/article/2646055" /><link rel="alternate" href="android-app://com.seekingalpha.webwrapper/http/seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript" /><meta name="syndication-source" content="http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript"><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />
<meta property="og:title" content="VIVUS' (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript" />
<meta property="og:description" content="VIVUS, Inc. (NASDAQ:VVUS) Q3 2014 Earnings Conference Call November 5, 2014 4:30 PM ET Executives Dana Shinbaum - Corporate Development and IR Svai Sanford - Interim CFO Seth Fischer - CEO Analysts Mark Vignola - Needham &amp" />
<link rel="canonical" href="http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript" />
<meta name='viewport' content='width=1240'>
<script>
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
</script>

<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-5.newrelic.com","errorBeacon":"bam.nr-data.net","licenseKey":"c0370b1d43","applicationID":"334927,334964","transactionName":"cldeEUAJWgldEBsASkVRUwlXFRkWUA1D","queueTime":0,"applicationTime":63,"agentToken":null,"agent":"js-agent.newrelic.com/nr-476.min.js"}</script>
<script type="text/javascript">(window.NREUM||(NREUM={})).loader_config={xpid:"UwUUUlVXAQEH"};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o?o:e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({QJf3ax:[function(t,e){function n(t){function e(e,n,a){t&&t(e,n,a),a||(a={});for(var c=s(e),f=c.length,u=i(a,o,r),d=0;f>d;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(5),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,window.onerror=e,NREUM.noticeError=n;try{throw new Error}catch(f){"stack"in f&&(t(1),t(4),"addEventListener"in window&&t(2),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&t(3),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:8,2:5,3:9,4:7,5:20,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],4:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(2);t("loader").features.stn=!0,t(1),n.on("fn-start",function(t){var e=t[0];e instanceof Event&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof Event&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:6,2:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=(t(1),t("ee").create()),i=t(2)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t){if(t[1]){var e=t[1];"function"==typeof e?this.wrapped=t[1]=a(e,"nr@wrapped",function(){return i(e,"fn-",null,e.name||"anonymous")}):"function"==typeof e.handleEvent&&i.inPlace(e,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:20,2:21,ee:"QJf3ax",gos:"7eSDFh"}],6:[function(t,e){var n=(t(2),t("ee").create()),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState"],"-")},{1:21,2:20,ee:"QJf3ax"}],7:[function(t,e){var n=(t(2),t("ee").create()),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:21,2:20,ee:"QJf3ax"}],8:[function(t,e){function n(t,e,n){var r=t[0];"string"==typeof r&&(r=new Function(r)),t[0]=o(r,"fn-",null,n)}var r=(t(2),t("ee").create()),o=t(1)(r);e.exports=r,o.inPlace(window,["setTimeout","setInterval","setImmediate"],"setTimer-"),r.on("setTimer-start",n)},{1:21,2:20,ee:"QJf3ax"}],9:[function(t,e){function n(){c.inPlace(this,d,"fn-")}function r(t,e){c.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}var i=t("ee").create(),a=t(1),s=t(2),c=s(i),f=s(a),u=window.XMLHttpRequest,d=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=i,window.XMLHttpRequest=function(t){var e=new u(t);try{i.emit("new-xhr",[],e),f.inPlace(e,["addEventListener","removeEventListener"],"-",function(t,e){return e}),e.addEventListener("readystatechange",n,!1)}catch(r){try{i.emit("internal-error",[r])}catch(o){}}return e},window.XMLHttpRequest.prototype=u.prototype,c.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),i.on("send-xhr-start",r),i.on("open-xhr-start",r)},{1:5,2:21,ee:"QJf3ax"}],10:[function(t){function e(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function n(t){var n=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s[i],this.listener,!1);if(!n.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){n.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=e(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(n.cat=d.split(", ").pop())}}else n.status=0;r.cbTime=this.cbTime,o("xhr",[n,r,this.startTime])}}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1);t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=n,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,n){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=e(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof n.onload))&&i.end(n)}catch(e){try{a.emit("internal-error",[e])}catch(r){}}};for(var u=0;c>u;u++)n.addEventListener(s[u],this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof XMLHttpRequest&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:11,3:9,4:5,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],11:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):(o[t]||(o[t]=[]),void o[t].push(e))}var r=t("ee").create(),o={};e.exports=n,n.ee=r,r.q=o},{ee:"QJf3ax"}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info;if(t&&t.agent&&t.licenseKey&&t.applicationID&&c&&c.body){p.proto="https"===d.split(":")[0]||t.sslForHttp?"https://":"http://",a("mark",["onload",i()]);var e=c.createElement("script");e.src=p.proto+t.agent,c.body.appendChild(e)}}function r(){"complete"===c.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=window,c=s.document,f="addEventListener",u="attachEvent",d=(""+location).split("?")[0],p=e.exports={offset:i(),origin:d,features:{}};c[f]?(c[f]("DOMContentLoaded",o,!1),s[f]("load",n,!1)):(c[u]("onreadystatechange",r),s[u]("onload",n)),a("mark",["firstbyte",i()])},{handle:"D5DuLP"}],20:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=n},{}],21:[function(t,e){function n(t){return!(t&&"function"==typeof t&&t.apply&&!t[i])}var r=t("ee"),o=t(1),i="nr@wrapper",a=Object.prototype.hasOwnProperty;e.exports=function(t){function e(t,e,r,a){function nrWrapper(){var n,i,s,f;try{i=this,n=o(arguments),s=r&&r(n,i)||{}}catch(d){u([d,"",[n,i,a],s])}c(e+"start",[n,i,a],s);try{return f=t.apply(i,n)}catch(p){throw c(e+"err",[n,i,p],s),p}finally{c(e+"end",[n,i,f],s)}}return n(t)?t:(e||(e=""),nrWrapper[i]=!0,f(t,nrWrapper),nrWrapper)}function s(t,r,o,i){o||(o="");var a,s,c,f="-"===o.charAt(0);for(c=0;c<r.length;c++)s=r[c],a=t[s],n(a)||(t[s]=e(a,f?s+o:o,i,s,t))}function c(e,n,r){try{t.emit(e,n,r)}catch(o){u([o,e,n,r])}}function f(t,e){if(Object.defineProperty&&Object.keys)try{var n=Object.keys(t);return n.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(r){u([r])}for(var o in t)a.call(t,o)&&(e[o]=t[o]);return e}function u(e){try{t.emit("internal-error",e)}catch(n){}}return t||(t=r),e.inPlace=s,e.flag=i,e}},{1:20,ee:"QJf3ax"}]},{},["G9z0Bl",3,10,4]);</script>
<link href="http://static3.cdn-seekingalpha.com/stylesheets/packaged/performance_layout_packaged.css?1415180553" media="screen" rel="stylesheet" type="text/css" /><link href="http://static1.cdn-seekingalpha.com/stylesheets/packaged/performance_layout_b_packaged.css?1415288306" media="screen" rel="stylesheet" type="text/css" /><link href="http://static2.cdn-seekingalpha.com/stylesheets/packaged/article_packaged.css?1415180553" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var siteon = false; var atest = true; var acounter = 0;</script>
<script type="text/javascript" src="/javascripts/siteon.js"></script>
<script type="text/javascript">
  window.primaryMarketCap = 340900749;
  window.primaryTickerSlug = "vvus";
  var users_on_site='3,922,999';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }


  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();

  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }


  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];

  //retry loading siteon
  if (!siteon) document.write('<'+'script type="text/javascript" src="/javascripts/siteon.js"><'+'/script>');
</script>

<script src="http://static2.cdn-seekingalpha.com/javascripts/packaged/common_packaged.js?1415180489" type="text/javascript"></script>
<script src="http://static3.cdn-seekingalpha.com/javascripts/packaged/common2_packaged.js?1415288306" type="text/javascript"></script>
<script src="http://static3.cdn-seekingalpha.com/javascripts/packaged/coffee_packaged.js?1415180494" type="text/javascript"></script><script src="http://static.cdn-seekingalpha.com/javascripts/packaged/common_article_packaged.js?1415180496" type="text/javascript"></script><script src="http://static.cdn-seekingalpha.com/memcached2/symbol_rt_data"></script>
<script type="text/javascript" src="http://static.cdn-seekingalpha.com/javascripts/senna.js?body=1"></script>
<script>
  try{
    new window.Senna(window.experiments || []).run()
  } catch (e) {
    Mone.event("error","senna","exception",{data:{exception: e.message}});
  }
</script>

<script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
  (function(){
    var url='/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript';
    if (location.pathname!=url && window.history && history.replaceState){
      history.replaceState("", "", url+location.search+location.hash);
    }
  })();
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}

</script>

      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
      GA_googleAddSlot_sa('transcript_120x30');
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>
  var ms_slug = '';
  var article_dashboards = 'transcript';
  var article_sectors_themes = '@transcripts@us@biotechnology@healthcare@article@';
  var ratings_hash={}
  var ARTICLE_ID = 2646055 ;
  var ARTICLE_TYPE = 'transcript';
  var ARTICLE_LOCK = "";
  var availableABVersions=["ver_a"];
  var abOBJ = new ABTest('transcript_pagination', availableABVersions);
  var machine_id = cookieExists('machine_cookie') ? parseInt(readCookie('machine_cookie')) : 0;
  var abVersion = abOBJ.value;
  var sliceSize = 4000;
  var isTranscript = true;
  var insight_sector = null;
  var isWebcast = false;
  var author_tag_id = 96991;
  var author_slug = "sa-transcripts";

  try {window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');}
  catch (error) {}
</script>
<script>var mone_article_tags = "{vvus};;;{healthcare};;;{transcripts,us,biotechnology};;;{sa-transcripts}"</script>

<script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation" itemscope itemtype="http://schema.org/Organization">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a itemprop="url" href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            SA.Utils.Ads.add({el:$('top_banner_728x90'), HadCreated:false, size:'728x90', delta: null, NotSticky: true, info:'http://ad.doubleclick.net/N6001/adj/sek.earnings/reports;sz=728x90;x=x;tile=1;d=earnings;t=reports;aid=2646055;d=sectors;t=transcripts;t=us;t=biotechnology;t=healthcare;t=article;z=1;a=sa-transcripts;cnt=7;cnt=20;cnt=24;cnt=37;cnt=41;pr=vvus;s=vvus;'+dart_my_vocation_and_profiles()+'ord='+ord+'?', pos_key: 'sz=728x90,tile=1'});
            SA.Utils.Ads.run();
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
        <li thistab='home' class="home">
          <a href="http://seekingalpha.com/" sasource="headtabs" style="font-size: 14px">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs" style="font-size: 14px">My Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a href="http://seekingalpha.com/news/all" sasource="headtabs" style="font-size: 14px">Breaking News</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='analysis'>
          <a href="http://seekingalpha.com/analysis/all" sasource="headtabs" style="font-size: 14px">Latest Articles</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='stocktalks'>
          <a href="http://seekingalpha.com/stocktalks/all" sasource="headtabs" style="font-size: 14px">StockTalk</a>
          <span class="navi_right_corner">|</span>
        </li>

        <li thistab='alerts' id='menu_alerts_tab'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs" style="font-size: 13px">ALERTS</a>
              <span class="navi_right_corner">|</span>
              </li>
              <li thistab='pro' class="pro_tab">
                <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
              </li>
          <li class="right_section">
            <div id="user_settings_wrapper"></div>
          </li>
          </ul>
    </div>
  </div>
  <div style='display:none' class="rta_nav etf_hub">
      <span class="rta_nav_wrap">
        <div>To screen ETFs by asset class, performance, yield and more, check out the <a href="/etf_hub" sasource="etf_performance" >ETF Hub.</a> <a  sasource="etf_performance" href="/etf_hub" id="etf_hub_button">ETF HUB</a></div>
      </span>
  </div>
</div>

  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>

<div id="main_container" class="transcript_page">
    <script>
      if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) $('main_container').addClassName('show_left_cont');
    </script>
     <div class='left_cont'>
        <div class="stickyad_wrapper">
          <div class="item banner160x600" id="fixed_banner160x600">
            <script type="text/javascript">
              function setAD(){
                if($('fixed_banner160x600').select('iframe')[0]) return;
                iframeAd("160x600",'http://ad.doubleclick.net/N6001/adj/sek.earnings/reports;sz=160x600;x=x;tile=3;d=earnings;t=reports;aid=2646055;d=sectors;t=transcripts;t=us;t=biotechnology;t=healthcare;t=article;z=1;a=sa-transcripts;cnt=7;cnt=20;cnt=24;cnt=37;cnt=41;pr=vvus;s=vvus;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');
                Mone.article_shown_left_ad = true;
              }
              if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) setAD();
            </script>
          </div>
        </div>
          </div>
  <div id="content_wrapper" itemscope itemtype="http://schema.org/Article" class="article_pages">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
     <div id="main_content" class='no_big_gaps_main_content'>
      <div id="" class="no_big_gaps_secondary_ads">
        <div id='article_top_info'>
    <a href='/author/sa-transcripts' sasource='auth_header_pic'><img id='author_info_img' class="author_img" align="center" src="http://static1.cdn-seekingalpha.com/images/users_profile/000/101/639/big_pic.png?1361390225" width="66px" height="66px" /></a>
    <div class='info_content'>
      <div>
        <a itemprop="author" class='author_name' href='/author/sa-transcripts' id='author_info_name' rel='author' sasource='auth_header_name'>SA Transcripts</a>,
          <a class='author_nick link' href="http://seekingalpha.com/analysis/transcripts/all" target='_blank' onclick='if (!/@seekingalpha.com/.test(SA.Data.User.email())) Mone.event("article", "auth_header_link", "44211", {data: {"url":"http://seekingalpha.com/analysis/transcripts/all","text":"Recent earnings call transcripts","name":"SA Transcripts","bio":"We cover over 5K calls/quarter"}})'>Recent earnings call transcripts</a>
          <span class="clicks">(41,317 clicks)</span>
      </div>
      <div>
        <span class='author_desc'>We cover over 5K calls/quarter</span>
      </div>
      <div>
        <a href='/author/sa-transcripts' sasource='auth_header_profile' class="author_action">Profile</a><span class='sep'>|</span>
        <span class='author_action' onclick='Messaging.sendMessagePopup("1aoxskmd","article_auth_header")'>Send Message</span><span class='sep' id='hider'>|</span>
        <div id="mover" class="di">
          <span id="rollover_menu" style="display: none;" onmouseleave="ArticlePage.hideRolloverMenu()">
            <div class="arrow"></div>
            <span id="rollover_content">
              <div class="rta_bottom">
                <div class="m_pop point_left" id="promotion_box_rel">
                  <div id="close_rollover" class="tr cp">x</div>
                    <div class="m_pop_inner">
                      <div class="popup_header">Author Following Options:</div>
                      <div class="popup_row_first">
                        <div class="popup_row_header">
                          <div class="preloader_popup_ab" style="float: left;">
                            <input type="checkbox" id="follow_author_checkbox" style="margin-right: 5px;">
                          </div>
                          Follow this author
                        </div>
                      <div class="popup_row_footer">See their articles on your Seeking Alpha homepage and in your feed.</div>
                    </div>
                    <div class="popup_row_second">
                      <div class="popup_row_header">
                        <div class="preloader_popup_ab" style="float: left;">
                          <input type="checkbox" id="get_rta_author_checkbox" style="margin-right: 5px;">
                        </div>
                        <div id="max_rta_header">Real-time alerts on this author</div>
                      </div>
                      <div id="max_rta_footer" class="popup_row_footer">Get their new articles emailed to you as they are published.</div>
                    </div>
                    <div class="popup_row_last">
                      <div class="popup_row_header">
                        <div class="preloader_popup_ab" style="float: left;">
                          <input type="checkbox" id="subscribe_digest" style="margin-right: 5px;">
                        </div>
                        Daily digest on all my authors
                      </div>
                    </div>
                    <div class="popup_row_footer">Get all your favorite authors’ new articles emailed to you in one daily digest.</div>
                  </div>
                  <div class="cleaner"></div>
                </div>
              </div>
            </span>
          </span>
          <span id="msg_popup"></span>
          <span id='follow_btn' class="follow_button_author" onclick="ArticlePage.toogleFollowAuthor('article_auth_header')" onmouseover="ArticlePage.showRolloverMenu()"></span>

          <span id="ballon_container"></span>

          <span id="follow_only_top"></span>
          <span class='clicks'>
            (<span id='follow_clicks' class='follow_clicks_author'>2,755</span> followers)
          </span>
          <span style="position:relative">&nbsp;<span id="follow_loader" class="follow_loader_author" style="display:none"></span></span>
        </div>
      </div>
      <div class='arr_up'></div>
    </div>
    <script>
      SA.Pages.Article.Follow.init('sa-transcripts');


      Mone.articleAuthorLinkShown = true;

    </script>
</div>




      </div>
       <div id='top_author_details'>
         <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="headline">VIVUS&#x27; (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript</span>
              </h1>
      <div id="article_info">
        <div class="article_info_pos">
          <span itemprop="datePublished" content="2014-11-06T00:18:05Z">Nov.  5, 2014  7:18 PM ET</span>
          <span id='title_article_comments'></span>
          <span class="print_hide"><span class='print_hide'>&nbsp;|&nbsp;</span> <span>About:</span> <span id='about_primary_stocks'><a href="/symbol/VVUS" title='Vivus, Inc.' sasource='article_primary_about_trc'>Vivus, Inc. (VVUS)</a></span></span>
          <span class="author_name_for_print">by: SA Transcripts</span>
            <span id="second_line_wrapper"></span>
        </div>
        <div class="article_disclosure">
          
        </div>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>

       </div>
        <div id="article_body_container" class="no_big_gaps_article_body_container">
          <div id="article_body" itemprop="articleBody">
            <div id="article_participants" class="content_part hid">
  <p>VIVUS, Inc. (NASDAQ:<a href='http://seekingalpha.com/symbol/vvus' title='Vivus, Inc.'>VVUS</a>)</p>
<p>Q3 2014 Earnings Conference Call</p>
<p>November 5, 2014 4:30 PM ET</p>
<p><strong>Executives</strong></p>
<p>Dana Shinbaum - Corporate Development and IR</p>
<p>Svai Sanford - Interim CFO</p>
<p>Seth Fischer - CEO</p>
<p><strong>Analysts</strong></p>
<p>Mark Vignola - Needham &amp; Company</p>
<p>Steve Byrne - Bank of America Merrill Lynch</p>
<p>Bob Ai - WallachBeth Capital</p>
<p>Matthew Andrews - Wells Fargo Securities</p>
<p>Shaunak Deepak - Jefferies</p>
</div>

<div id="article_content" class="content_part hid">
  <p></p>
<p><strong>Operator</strong></p>
<p>Good day, ladies and gentlemen, and welcome to the VIVUS Third Quarter 2014 Financial Results Teleconference. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this teleconference is being recorded.</p>
<p>And now, I'll turn the program over to Mr. Dana Shinbaum, Corporate Development and Investor Relations. Please go ahead.</p>
<p><strong>Dana Shinbaum</strong></p>
<p>Thank you. Before we get started, I would like to remind you that during this conference call, VIVUS will make certain statements that are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as anticipate, believe, estimate, expect, forecast, intend, likely, may, opportunity, plan, potential, predict and should, among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in the VIVUS’ Form 10-K for the year ended December 31, 2013, as filed on February 28, 2014 and as amended by the Form 10-K/A filed on April 30, 2014 and periodic reports filed with the Securities and Exchange Commission.</p>
<p>I will now turn the call over to Mr. Seth Fischer, CEO of VIVUS.</p>
<p><strong>Seth Fischer </strong></p>
<p>Hello, everyone and welcome to our third quarter 2014 financial results teleconference. Joining me today in addition to Dana, is Svai Sanford, Interim CFO.</p>
<p>Today, we will review with you our financial results and progress made during the most recent quarter. The market for obesity pharmacotherapy remains both a challenged and an enormous opportunity with a high degree of unmet medical need and new therapeutic options including Qsymia entering Lexicon. While the obesity market develops we’re encouraged by an improving reimbursement environment for Qsymia, increasing net revenue per prescription and feedback from clinicians who emphasize that our product delivers on the promise of clinically significant weight loss.</p>
<p>We continue to focus our commercial campaign for Qsymia on the most productive and potentially productive prescribers within the anti-obesity market. We believe there is room to expand Qsymia utilization within these audiences. Healthcare providers report greater willingness to treat an increasing use of prescription medication as part of their treatment approach for obesity. However, challenges remain with respect to building the obesity market and translating self-reported perceptions into prescribing reality. These challenges include the tendency to treat symptoms of obesity ahead of the disease itself. A narrow focus on certain patient types for treatment, historically low third-party coverage and Medicare Part D exclusion among others.</p>
<p>Qsymia prescriptions have been relatively flat on a weekly and monthly basis throughout the current quarter. Promotional efforts in support of unique efficacy and tolerability profile of Qsymia have helped hold market share stable among our targeted physicians in the face of increasing competitive noise. Market research indicates that clinical experience, specifically efficacy, growing familiarity and overall satisfaction with Qsymia, our natural product advantages driving the steady prescription trend in the most recent quarter.</p>
<p>Type-2 diabetes and sever obesity are the primary factors reported by clinicians for prompting drug therapy prescribing. Dr. Timothy Garvey of UAB was the lead author of a recent paper in diabetes care that highlighted the positive impact on glycemic control of Qsymia when combined with lifestyle modification and overweight or obese patients with type-2 diabetes over a broad range of severity. Among the study conclusions was the observation that Qsymia plus lifestyle modification has a significant impact on cardio metabolic parameters, particularly with respect to HbA1c lowering and can be considered integral to the treatment of obese and overweight patients with type-2 diabetes.</p>
<p>Third-party coverage for Qsymia excluding free trial offer prescriptions stood at 37% for the second quarter of 2014 and reached 38% for the current quarter. These percentages represent actual third-party payors paying for Qsymia not estimates derived from external databases. As a point of comparison, the commercial coverage rate for Qsymia is 67% when we look to industry databases such as Fingertip Formulary. Payors continue to evaluate whether or not to cover the obesity category rather than whether to cover specific products. Formulary physicians and peer discussions are important, but only after a payor makes the decision to cover the obesity class for its members. Without clinical data pharmacoeconomic profile and contracting offers we believe reimbursement for Qsymia will continue to improve.</p>
<p>Regarding our plans for Qsymia in Europe, as you are aware we modified the design of the Phase 4 CVOT trial required for Qsymia by the FDA in order to establish a potential pathway to European approval through the centralized European Union procedure. We received helpful feedback earlier this year from European Union regulatory officials regarding the AQCLAIM CVOT protocol, and we also received feedback from U.S. FDA regarding the amended protocol. As a part of addressing the FDA comments, we are working to ensure that the planned interim analysis will not jeopardize the overall integrity of the study and will support other objectives in both the EU and U.S.</p>
<p>Our Qsymia partnering efforts are ongoing and we remain open to establishing commercial alliances for Qsymia on a global or regional basis if they create value for stockholders. We cannot provide guidance with respect to the timing or structure of a potential partnership, but we intend to update the market when appropriate regarding any material developments.</p>
<p>Throughout the balance of 2014 and as we prepare for 2015, we will watch closely how the market continues to develop while controlling our cost. We will increase promotional activity in support of Qsymia when it is appropriate and efficient for investment purposes. We believe that the foundation of the obesity market has been and will continue to be education of healthcare providers and allied professionals regarding the need to treat obesity with the proper clinical tools, including increased diet and exercise along with effective, safe and well-tolerated pharmacotherapy such as Qsymia. We plan to continue to deliver this message through in-person promotion, continuing medical education and peer-to-peer programs, clinical publications, participation in major scientific meetings such as Obesity Week here in Boston and select direct-to-patient opportunities in healthcare provider offices.</p>
<p>Turning now to avanafil, we are pleased to be working with Auxilium, Menarini and Sanofi, our commercial alliance partners for avanafil in the U.S., Europe and certain rest of world territories respectively. Auxilium launched STENDRA in the U.S. in December 2013 and as of April 2014 Menarini completed the launch of SPEDRA in the EU-5. SPEDRA is now available at retail in approximately 23 countries within the Menarini territory. We were pleased to announce in September that the FDA had approved a supplemental new drug application for STENDRA making it the only FDA approved erectile dysfunction medication indicated to be taken as early as approximately 15 minutes before sexual activity. We’re also working with European regulatory authorities with respect to these data for the SPEDRA label. For Latin America and certain Asian countries, we are in discussions with potential partners for license and commercialization arrangements.</p>
<p>I will now pass the call over to Svai Sanford our Interim CFO for an update on the financials.</p>
<p><strong>Svai Sanford</strong></p>
<p>Thank you, Seth. Good day everyone. I will now discuss our financial results for the third quarter ended September 30, 2014. I also refer you to the financial results and recent updates included in our press release.</p>
<p>Total net revenue was 33.9 million for the third quarter of 2014 compared to 27.4 million for the third quarter of 2013. Of the total revenue for the current quarter, net product revenue was 12.5 million from sales of Qsymia compared to 6.4 million for the third quarter of 2013. In addition, under our commercialization agreement for STENDRA and SPEDRA, we recognized 15.1 million in license and milestone revenue compared to 21 million in the third quarter of 2013. We also recognized 5.3 million in supply revenue and 1.1 million in royalty revenue for the current quarter.</p>
<p>The license and milestone revenue in the current quarter represents a milestone payment earned for the FDA approval at the time of onset claim for STENDRA. The supply revenue represents product shipment to our commercialization partners. There were approximately 140,000 Qsymia prescriptions dispensed in the third quarter of 2014 compared to 138,000 prescriptions in the second quarter of 2014 and 109,000 in the third quarter of 2013. Approximately 63% of Qsymia total prescription in the current quarter included either a free good or discount offer compared to 61% in the second quarter 2014 and 56% in the third quarter 2013.</p>
<p>Net revenue per prescription for the current quarter excluding free trial offer prescription reached $113, up from $102 in the second quarter 2014 and $79 in the third quarter 2013. Including free trial offer prescription, net revenue per prescription for the current quarter was $89 compared to $80 in the second quarter 2014 and $59 for the third quarter 2013.</p>
<p>As a reminder, we recorded revenue from sales of Qsymia on a sell-through method, whereby revenue is recognized when a prescription is dispensed to a patient. As of September 30, 2014 our deferred revenue related to sales of Qsymia is 16.3 million, which represents product shift to wholesaler but not yet dispensed to patients via prescription. Total cost of goods sold was 7.3 million for the current quarter compared to 0.7 million in the third quarter of 2013. The increase is primarily due to the cost of STENDRA supply and certain patent acquisitions and assignments related to Qsymia.</p>
<p>Total research and development expense was 2.6 million for the current quarter compared to 8.4 million for the third quarter 2013. The decrease is primarily due to the completion of studies related to STENDRA, timing of Qsymia study and lower employee cost as a result of the 2013 reduction in force. Total selling, general and administrative expense excluding non-recurring charges was 27.8 million in the current quarter compared to 38.2 million in the third quarter 2013. Selling and marketing expenses for the commercialization of Qsymia were 18.4 million for the current quarter compared to 22.6 million for the third quarter 2013.</p>
<p>The decrease in selling and marketing expense was due primarily to our targeted and focused spending on marketing and promotional programs. The decrease in general and administrative expense was due primarily to factors attributable to our cost cutting initiatives including reduction in headcount and other employee cost, including share-based compensation expense. Lower spending on profession fees, grant cost for continuing education program and other corporate activities.</p>
<p>Inventory impairment and other non-recurring charges were 4.1 million in the current quarter comprised of 2.2 million for inventory impairment and 1.9 million for patent settlement. In the third quarter of 2013 we incurred 20.7 million in non-recurring charges related to the proxy contest of which 12.7 million was non-cash share-based compensation expense. Net loss was 16.8 million or $0.15 net loss per share for the current quarter compared to a net loss of 48.2 million or $0.48 net loss per share for the third quarter of 2013.</p>
<p>Cash, cash equivalent and available for sale securities, collectively cashed total 306.9 million at September 30, 2014 compared to 343.3 million at December 31, 2013. In the first nine months of 2014, we received approximately 27.4 million in license and milestone payments related to STENDRA and SPEDRA. Excluding such amount, our net cash used in operating activity would have been 59.3 million.</p>
<p>I will now turn the call back to Seth, for closing comments.</p>
<p><strong>Seth Fischer</strong></p>
<p></p>
<p>We continue to work with a broad range of constituents from prescribers to medical societies to grassroots organizations, to gain acceptance of obesity as a disease and adoption of Qsymia as the drug of choice among healthcare providers, payors, and patients. The areas of focus for VIVUS for the balance of 2014 and into 2015 remain as follows; deliver a strong efficacy and safety message about Qsymia to key healthcare provider audiences; target the most appropriate patients and the healthcare providers most likely to treat those patients; continue to improve overall Qsymia insurance coverage; continue to improve per prescription Qsymia net revenue; continue our efforts to secure a partner for Qsymia; and manage our avanafil alliances with Auxilium, Menarini and Sanofi to help insure the commercial success of this important erectile dysfunction medication around the world. In addition, we will continue to discuss it with potential partners for STENDRA and SPEDRA commercial alliances in Latin America and certain territories in Asia.</p>
<p>We’re now pleased to take your questions.</p>
</div>

<div id="article_qanda" class="content_part hid">
  <p><strong>Question</strong>-<strong>and</strong>-<strong>Answer Session</strong></p>
<p></p>
<p><strong>Operator</strong></p>
<p></p>
<p>Thank you. (Operator Instructions) Our first question comes from the line of Alan Carr from Needham &amp; Company.</p>
<p><strong>Mark Vignola </strong>- <strong>Needham &amp; Company</strong></p>
<p></p>
<p>Hi guys, this is actually Mark on for Alan. Thanks for taking by questions, just a few quick housekeeping questions I was just wondering if you could repeat the percent of free goods for the quarter?</p>
<p><strong>Svai Sanford</strong></p>
<p></p>
<p>Hi Mark, it’s Svai, it's 21%, the free good.</p>
<p><strong>Mark Vignola </strong>- <strong>Needham &amp; Company</strong></p>
<p></p>
<p>21% of the prescriptions were -- represented free good and that was versus what for the second quarter?</p>
<p><strong>Svai Sanford</strong></p>
<p></p>
<p>22.</p>
<p><strong>Mark Vignola </strong>- <strong>Needham &amp; Company</strong></p>
<p></p>
<p>22, okay, so I was wondering in the press release you guys say that Qsymia is top of mind in many conservations I was wondering how are you guys gauging that and do you see any change over quarter-end in whatever metrics you’re using to change that at level of the last quarters to maybe yours beginning of the year?</p>
<p><strong>Seth Fischer</strong></p>
<p>So we have ongoing surveys in the market both with physicians and consumers. So we try to look overtime as to what is the first of all of concept of pharmacotherapy and how much that is increasing overtime, as well as the name of Qsymia increasing overtime. And we do see that continuing to progress, actually even this week as compared to last year at Obesity Week compared to this year we are seeing a lot more interest on the four and our product with a lot more activity from registered nurses, nurse practitioners, bariatric surgeons, bariatric medicine, where they are becoming attuned to the use of pharmacotherapy in their practice. And specifically very nice success stories with Qsymia in particular.</p>
<p><strong>Mark Vignola </strong>- <strong>Needham &amp; Company</strong></p>
<p>And regarding the CVOT trial, are there any timeline updates or updates you can provide on when we might actually get that started I am sorry if I missed that during the call?</p>
<p><strong>Seth Fischer</strong></p>
<p>I don’t really have a timeline update for start. I can tell you that as I said during the call we’ve had to make sure that we have clear alignment between the European regulatory authorities and FDA. And clearly going back to August 11th’s FDA’s guidance and their advisory panel about the integrity of these trials, we want to absolutely ensure that everything we’re doing to allow us to do an interim analysis with the European regulatory authorities is very clear so that in no way do we ruin the integrity of the trial through that interim analysis. so that’s really what we’re making sure we ensure there is a lot of learnings in the market both on the good side as well as on the bad side and we want to make sure that we’re all aligned on how we will in fact do that.</p>
<p><strong>Operator</strong></p>
<p>Thank you. Our next question comes from the line of Steve Byrne from Bank of America.</p>
<p><strong>Steve Byrne </strong>-<strong> Bank of America Merrill Lynch</strong></p>
<p>Seth can you help me which what seems like a disconnect between the fraction of your scripts that received insurance coverage versus this third-party metric that you have that would suggest nearly twice as many, twice the portion of patients should have coverage. Why is there such a difference there?</p>
<p><strong>Seth Fischer</strong></p>
<p>Well, I believe that the numbers that you’ve heard Steve is that 48% of people have access meaning if they want the medication they have access to it. The other number, which is purely coverage and let me define how I define coverage those are absolute prescriptions. So Qsymia prescriptions actually paid for a third-party is 38% there is a lot of other numbers that are quoted by a lot of other people and one of the main things that they’re quoting which you can go get online and see for yourself is in fact Fingertip Formulary. But I prefer to really state the actual coverage we’re seeing, which is about 38%. We also see on Managed Care right now that there is still struggling whether they’re going to cover the category we don’t see a huge difference in coverage between any of the current pharmacotherapies whatsoever. Some slight differences to tiers whether they are tier 3 or tier 2 but even the majority of those are tier 3 still many with the prior authorization. So I want to be clear on the numbers which I think I also stated earlier.</p>
<p><strong>Steve Byrne </strong>-<strong> Bank of America Merrill Lynch</strong></p>
<p>And putting aside the cardiovascular outcome study that you will at some point here startup do you anticipate sufficient increase in scripts and average selling price and so forth to reach a cash flow breakeven point in the intermediate term? Can you comment on that?</p>
<p><strong>Seth Fischer</strong></p>
<p>Well we’re continuing to do everything we can to obviously increase our scripts with physicians also increase coverage with payors. We will start the CVOT trial we know that does put pressure, but we think that we’re doing the right things by watching our cost at the same time not getting in the way of increasing our prescriptions with our key physicians.</p>
<p><strong>Steve Byrne </strong>-<strong> Bank of America Merrill Lynch</strong></p>
<p>And just to follow-up on that cardiovascular outcome study. You indicated you wanted to make sure there was no chance to jeopardizing the overall study from an interim analysis. Do I interpret that correctly that you want an interim read that you could use to file in Europe, but you don’t want those data to be publicly disclosed?</p>
<p><strong>Seth Fischer</strong></p>
<p>That is correct. We want to ensure that the company itself will not have exposure to the interim analysis. We want to make sure when that is in fact used for submission in Europe that there is no chance that the European authorities or anybody else can divulge that information thereby breaking the blind on the trial. And that’s as you know this has happened recently to some other companies in the space and we want to ensure that it doesn’t happen here.</p>
<p><strong>Operator</strong></p>
<p>Thank you. Our next question comes from the line of Bob Ai from WallachBeth.</p>
<p></p>
<p><strong>Bob Ai </strong>- <strong>WallachBeth Capital</strong></p>
<p></p>
<p>Hi, I just want to confirm something about 47% or 48% of the scripts are paid by insurance companies and without any financial assistance or simply using the similar card, is that correct?</p>
<p><strong>Seth Fischer</strong></p>
<p></p>
<p>So 38% are paid for by third-party they still may use a co-pay card but it means that there was absolute insurance assistance in the payment so co-pays can vary, we’ve a program that in fact that the co-pay is above $50 that we will give assistance up to $125 so basically reducing the co-pay by $75 and then if you are a cash patient, fairly cash patient, we’ll give you $75 off. We also have a Qsymia access program virtually helps patient get qualified for Qsymia they call a 800 number if you will to actually have the third-party look at with their potential coverage is and give them assistance whether it would prior authorization or actually qualifying them for assistance.</p>
<p><strong>Bob Ai </strong>- <strong>WallachBeth Capital</strong></p>
<p></p>
<p>I think about it back to about two quarters back and you’re talking about you’re trying to change the discounted program than to trying to raise the average selling price, have we reached that goal yet or we are still in the process of doing that?</p>
<p><strong>Seth Fischer</strong></p>
<p></p>
<p>No, as we just stated we’ve improved our average selling price I’ll let Svai take you through the numbers.</p>
<p><strong>Svai Sanford</strong></p>
<p></p>
<p>So, up to the end of the first quarter of this year we had to pay no more than $75 that program ended at the end of Q1 some of the coupon that might have been activated prior to that were being used through the end of May or June and then at that time we introduced the $75 off if you would recall and that $75 off discount program applies to all doses as opposed to the pay no more than 75 which only applied to the mid dose. So the change in the program is also there was a limitation of three months of usage in our old discount program. Today with the $75 off that discount card can be used up to 12 times by a patient.</p>
<p><strong>Bob Ai </strong>- <strong>WallachBeth Capital</strong></p>
<p></p>
<p>The last question is, so I understand you are trying to cut cost and trying to reduce cash burn but this is -- you can only cut so much, and have you thought about other ideas and maybe like a in licensing some complementary products that you can help reduce the burn rate?</p>
<p><strong>Seth Fischer</strong></p>
<p></p>
<p>Yes, we were looking at all options I mean that includes some of the ones that you just outlined whether it be licensing other compounds obviously we’ve got a very strong development group within the company who managed to get the approval of two drugs in the same calendar year so we believe in them and we’re always looking at other potential licensing compounds as we’ve favored partnerships and other creative ways to help the growth of the company.</p>
<p><strong>Operator</strong></p>
<p></p>
<p>Thank you. (Operator Instructions) Our next question comes from the line of Matthew Andrews from Wells Fargo Securities.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p></p>
<p>Seth, so what are the pacing items for the initiation of the outcome study, the public comment period for the FDA’s hearing on August 11th ended recently, so are you waiting for FDA to publish a white paper or do you have to have a face-to-face meeting with them, what’s the Gantt chart looked like in terms of getting their buying on these issues you’ve outlined in the interim analysis?</p>
<p><strong>Seth Fischer</strong></p>
<p></p>
<p>So, we need to -- obviously we’ve been through the call or the advisory board to really ensure that we understand fully what they’re looking for. We’re also talking to our own advisors to ensure that we are covering the issues that they outlined we, some of those very advisors at that board, we’re involved with the trial itself so we want to ensure that we understand what it means. There is some still issues that we need clarification on, I’m not sure that those will come directly from the FDA, I think the FDA is trying to be pretty clear that you need to really protect the integrity overall. So, we’re working with consultants, we’re building the infrastructure and we’re making sure that there is clear walls so that data does not get divulged in anyway and that takes a little bit extra time that we did not anticipate but the interim analysis is critical to that submission so we want to make sure we do it right.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p>So to be clear, at the end of this process will you have to meet with them or have a phone call at least or?</p>
<p><strong>Seth Fischer</strong></p>
<p></p>
<p>We have one final document that we have been preparing to submit to FDA I don’t see any further meetings with FDA no.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p>And then once you submit data, what’s the turnaround time look like? Is it open-ended situation or because this is a Phase 4 requirement you’d expect them to get back to you pretty quickly?</p>
<p><strong>Seth Fischer</strong></p>
<p></p>
<p>No we would expect once we’re able to submit data we can start fairly quickly.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p>And then the interim analysis is this still going to be based around like a 90 event at less than hazard ratio of 2, just with FDA guidance?</p>
<p><strong>Seth Fischer</strong></p>
<p>Yes, absolutely.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p>And is it being designed initially as a superiority study or as a non-inferiority and then you can upsize it depending on what’s seen as the study progresses?</p>
<p><strong>Seth Fischer</strong></p>
<p>Yes, it’s exactly how you just outlined the decision making trial will start as a non-inferiority trial with the idea that you have the way to power it up if you need to if you see signals of superiority.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p>But if that interim analysis you need to pre-specify hurdles and there is the potential to re-file in Europe?</p>
<p><strong>Seth Fischer</strong></p>
<p>Yes, that’s correct. That’s our understanding from the feedback that we have from the SAWP in January.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p>Have your cost estimates changed still maybe 180 million to 220 million?</p>
<p><strong>Seth Fischer</strong></p>
<p>Yes, that’s correct.</p>
<p><strong>Matthew Andrews </strong>-<strong> Wells Fargo Securities</strong></p>
<p>And then I guess just lastly on fourth quarter. Historically it’s been a tough one for obesity drugs. So, in light of the flattish sales performance in the last few quarters and you have Contrave on the market and potentially STENDRA comes too. How confident are you that you can at least grow sales this quarter due to seasonality and competition and similarly first quarter next year?</p>
<p><strong>Seth Fischer</strong></p>
<p>So, it’s interesting because to your point it’s a bit unprecedented. And we know that seasonality plays a role here. But I am also feeling good that there is a lot more noise in the marketplace. And I don’t know exactly how to read that yet. But I actually see it as a positive that we have including our own over 1,600 representatives talking about obesity in the marketplace which doesn’t even include the deployment of STENDRA yet. So, I think that the noise could be a very positive thing. Although we always we do see a downturn around Thanksgiving and Christmas. We may see that but I am wondering how the market may be bolstered by additional noise into the marketplace. And I can’t really predict that right now.</p>
<p><strong>Operator</strong></p>
<p>Thank you. And our next question comes from the line of Shaunak Deepak from Jefferies.</p>
<p><strong>Shaunak Deepak </strong>-<strong> Jefferies</strong></p>
<p>I want to talk just a little bit more about this competitive noise and I was just kind of curious like near-term like what kinds of impacts have you seen like the launch of Contrave have on your sales efforts? And then like what kinds of expansions do you expect for your sales efforts in 2015 in addition to like potential future partnership on that front?</p>
<p><strong>Seth Fischer</strong></p>
<p>So in terms of the additional noise in the marketplace it’s probably a little early for us to fully tell the impact of Contrave they’ve only really been out in the market for a few weeks now. And the good news is they are reaching audience is that we don’t have the capability or made the decision to in fact reach at this point. So we have a very clear targeted audience. And these are the most productive anti-obesity pharmacologic writers in the market and that’s where we will remain focused. If we see physicians that are coming onboard and actually getting motivated to write we still believe even with our current 150 sales reps that we have capacity to reach those physicians.</p>
<p>And then overtime we will look at whether we need to expand to reach further -- reach further doctors that are writing in the category. And then as the market is obviously being watched by people interested in the market and the uptake in the market and whether the market begins to expand. We’ve seen the market basically grow in mid single-digits. I am hopeful that the market will expand. And I believe with all the noise which we haven’t seen in this market forever that it will expand.</p>
<p><strong>Shaunak Deepak </strong>-<strong> Jefferies</strong></p>
<p>And then I just had one more on avanafil. And I was curious about like the remaining sort of un-partnered territories in Latin America and Asia you were talking about. When you are looking for potential partnerships are you thinking more if like a country-by-country basis or like a larger more encompassing almost global partnership on this and are you thinking more in Auxilium or Menarini pretty much?</p>
<p><strong>Seth Fischer</strong></p>
<p>So we’re very open to active discussions with partners and those are ongoing. Menarini, Sanofi, Auxilium they’re all very good partners. We’ve as you know licensed this out on a regional basis. We’re continuing to look at this as a regional license. Certainly some of those parties maybe involved some may not.</p>
<p><strong>Operator</strong></p>
<p>Thank you. And that concludes our question-and-answer session for today.</p>
<p><strong>Seth Fischer</strong></p>
<p>I want to thank everybody for attending our call today. We remain enthusiastic about the market overall. We are seeing continued interest growing from payors, providers and patients. And this is going to be extremely important as we go forward and continue to grow in the treatment of disease of obesity. Thank you very much.</p>
<p><strong>Operator</strong></p>
<p>Ladies and gentlemen, thank you for your participation in today’s conference. This does conclude the program and you may now disconnect. Everyone have a good day.</p>
</div>

<div id="article_disclaimer" class="content_part hid">
  
<p><strong>Copyright policy: </strong>All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: <strong>You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.</strong></p>

<p>THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.</p>
<p>If you have any additional questions about our online transcripts, please contact us at: <a href="mailto:transcripts@seekingalpha.com" rel="nofollow"><u>transcripts@seekingalpha.com</u></a>. Thank you!</p>

</div>

<div id="article_slice"></div>

<div class="cleaner"></div>

              <div id="article_source">Source: <a href="/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript?source=cc">VIVUS&#x27; (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript</a></div>
          </div>
          <div class="cleaner"></div>
          <div class="transcript_bottom_tabs">
            <ul id="tab_cmd" style="float:left;display:none;">
              <li id="tab_single_bottom" name="tab_single" style="border-width:0px !important;" onclick='if (SA.Data.User.loggedIn()) {transcriptRedirect("single")} else {transcript_rb_show()}'><span>Single page view</span></li>
              <li id="tab_search_bottom" class="last chosen" name="tab_search" style='display:none;border-left: 1px solid #C4C4C4;'><span>Search</span></li>
            </ul>
            <div id="pag_cmd" style="display:none;">
            	<div id="tab_prev_bottom" name="tab_prev" style="display:none;float:left"><a href="javascript:void(0)" onclick="abOBJ.convert('Prev Page');trascriptNextSlice(-1)">&laquo; Previous</a>&nbsp;|&nbsp;</div>
            	<div id="tab_pagination" style="float:left"> page <span id="current_page_index">1</span> / <span id="last_page_index"></span></div>
            	<div id="next_page" style="display:none;">|&nbsp;<a href="javascript:void(0)" onclick="abOBJ.convert('Next Page');trascriptNextSlice(1)">Next »</a></div>
            </div>
            <div class="cleaner"></div>
          </div>
            <div id="poll_end_article" style="display: none;">
    <div id="poll_question_options">
      <div id="poll_question" class="poll_title"><span id="poll_question_start">Now that you’ve read this, are you Bullish or Bearish on</span> <span class="primary_ticker_poll" id="primary_ticker_poll_question"></span>?</div>
      <div id="poll_options"><span id="poll_green_option" onclick="SA.Pages.Article.surveyEndArticle($('primary_ticker_poll_question').innerHTML,'bull')">Bullish</span><span id="poll_red_option" onclick="SA.Pages.Article.surveyEndArticle($('primary_ticker_poll_question').innerHTML,'bear')">Bearish</span></div>
    </div>
    <div id="poll_sentiment_options" style="display: none;">
      <div id="poll_title_answer" class="poll_title">Sentiment on <span class="primary_ticker_poll" id="primary_ticker_poll_sentiment"></span><span id="sentiment_votes"> (<span id="number_responses_poll"></span>)</span></div>
      <div id="poll_two_options">
        <div class="poll_options_names"><span class="fl">Bullish</span><span id="green_line_poll"></span><span class="gray_line_poll"></span><span id="percent_poll_green" class="percentage_poll_answers"></span></div>
        <div class="poll_options_names mt1"><span class="fl">Bearish</span><span id="red_line_poll"></span><span class="gray_line_poll"></span><span id="percent_poll_red" class="percentage_poll_answers"></span></div>
      </div>
      <div id="thanks_poll" style="display: none;">Thanks for sharing your thoughts.</div>
    </div>
    <div id="poll_why" style="display: none">
      <div id="poll_why_title" class="poll_why_title">Why are you <span id="poll_why_bb"></span>?</div>
      <div id="poll_why_textarea">
        <textarea id="text_submit_poll" maxlength="65000" ></textarea>
      </div>
      <div id="poll_submit_or_skip"><span id="poll_submit" onclick="SA.Pages.Article.submitBullBearWhy()">Submit & View Results</span><span id="poll_skip" class="link" onclick="SA.Pages.Article.skipClickedBullBearWhy()">Skip to results »</span></div>
    </div>
  </div>
          <script>OpenTranscriptPage("");</script>
          <div id="content_follow_up" class="transcript_follow_up">
            <div id="paging" class="transcript-paging"></div>
            <div id="article_bottom_about" class="article_bottom_units"></div>

            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this transcript with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',2646055,'http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="VIVUS&#x27; (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript?source=tweet $VVUS" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback" data-url="http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript?source=linkedin_share"></script></span>
    <!-- facebook -->
    <span id="span_fb_widget_like" class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <div id="span_fb_widget_share" style="display: none;margin:0 10px 0 0;" class="fb-like fl" data-href="http://seekingalpha.com/article/2646055-vivus-vvus-ceo-seth-fischer-on-q3-2014-results-earnings-call-transcript?source=facebook" data-layout="button" data-action="like" data-show-faces="false" data-share="false"></div>
    <!-- Plusone  -->
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
     //FB Share button test
     $('span_fb_widget_like').hide();
     $('span_fb_widget_share').show();
     setTimeout(function(){$('span_fb_widget_share').style.background="none";}, 15000);
     $('pluszone').setStyle({'margin-left':'5px'});


    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '2646055'
        }
      });
    });

  </script>

  </li>
</ul>
            </div>
            <div class="cleaner"></div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>

            <div id="bottom_rta_unit" class="cb"></div>

            <div class="transcript_center_link">
              <a href="/tag/transcripts" sasource="trans_lb_center">Seeking Alpha's Earnings Center</a>
              -- Broad coverage. Powerful search.<br/>And it's free...
              <span class="gray">Why are you paying for something less good?</span>
            </div>
          </div>
        </div>
    </div>
<div class="article_right_content">
<div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" id="autocomplete_sa_hidden_avoid_symbol" name="avoid_symbol" value="" />
      <input type="hidden" name="sort" value="date:d" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, Keywords:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
<script>if (window.showing_long_box) $$('.search_box_container_isolated')[0].hide();// abtest_site_search</script>
       <script>var page_ad_src = 'http://ad.doubleclick.net/N6001/adj/sek.earnings/reports;sz=300x251;x=x;tile=4;d=earnings;pos=b;t=reports;aid=2646055;d=sectors;t=transcripts;t=us;t=biotechnology;t=healthcare;t=article;z=1;a=sa-transcripts;cnt=7;cnt=20;cnt=24;cnt=37;cnt=41;pr=vvus;s=vvus;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>

<div id="ads_and_tools" class='transcript_sidebar_tools red_sidebar'>
  <div class="item banner300x600">
    <script>add_js_to_ad_call('http://ad.doubleclick.net/N6001/adj/sek.earnings/reports;sz=300x250,300x600;x=x;tile=2;d=earnings;pos=t;t=reports;aid=2646055;d=sectors;t=transcripts;t=us;t=biotechnology;t=healthcare;t=article;z=1;a=sa-transcripts;cnt=7;cnt=20;cnt=24;cnt=37;cnt=41;pr=vvus;s=vvus;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
  </div>
  <div id="alternative_title_container" class="mini_category data_currencies_table" style="display:none">
  <div class="sidebar_title_bk">
    <span class="sidebar_title_text" id="article_alternative_title"></span>			
  </div>
  <div id="symbol_alternative_tags" class="symbol_alternative_tags"></div>
  <div id="alternatives_pirsomet" class="alternatives_pirsomet" style="float:left;width:100%;"></div>
      <script type="text/javascript">
        ssga_always_display("transcript_120x30", "http://9nl.it/i3eb/");
      </script>
  <div class="cleaner"></div>
</div>

<script type="text/javascript">
  symbol = "VVUS";
  new Ajax.Request('/articles/get_ajax_alternatives_by_symbol?symbol='+symbol, {
    asynchronous:true,
    evalScripts:true,
    method:'get',
    onComplete: function(transport) {
      if (transport.status == 200 && transport.responseText != 'failed') {
        response = transport.responseText.split("@@");
        symbolZiignight = new Ziignight('', 'SAlternative',"","symbolZiignight","symbol_alternative_tags","ETF");
        symbolZiignight.WorkJSON = eval(response[1]);
        symbolZiignight.addETF = false;
        symbolZiignight.pageType = 'Article';
        symbolZiignight.selectedSymbol = symbol;
        symbolZiignight.SAlternativePrint(-1,true);
        symbolZiignight.InsertEtfAlternativeSymbol(response[0]);
        $('article_alternative_title').innerHTML = response[0].toUpperCase() + " vs. ETF alternatives";
        $("alternative_title_container").style.display = "";
      }
    }
  });
</script>


  <div id="block_find_in_transcript">    
    <div class="search_quote_transcripts">
      <div class="mini_category">
        <div class="sidebar_title_bk">
          <span class="sidebar_title_text">Search  transcript</span>
        </div>
        <form id="search_transcript_form_in_this" onsubmit="return false;">
          <span style="float:left;margin-top:7px;margin-right:10px;">This Transcript</span>
          <input type="hidden" value="-1" name="page" />
          <span id="search_box_text_field_span_in_this" class="shine_search_off">
            <input type="text" class="text" name="term" id="search_transcript_in_this" value='e.g. "this quarter"' title='e.g. "this quarter"' afterUploadValue='e.g. "this quarter"' onfocus="this.style.color='#000000';handleInput(this,'focus');" onblur="this.style.color=this.value=='' ? '#BCBCBC' : '#000000';handleInput(this,'blur');" autocomplete="off" onkeypress="if (event.keyCode==13) { find_in_relevant_search_in_this(); }" />
          </span>
          <input type="button" value="Find" class="submit" id="submit_search_transcript_in_this" onclick="find_in_relevant_search_in_this();" />
          <div id="word_not_found_message_in_this" class="word_not_found_message" style="display:none;">Text not found.</div>
        </form>
        <form id="search_transcript_form_in_all" onsubmit="return false;">
          <span style="float:left;margin-top:7px;margin-right:12px;">All Transcripts</span>
          <input type="hidden" value="-1" name="page" />
          <span id="search_box_text_field_span_in_all" class="shine_search_off">
            <input type="text" class="text" name="term" id="search_transcript_in_all" value='e.g. "this quarter"' title='e.g. "this quarter"' afterUploadValue='e.g. "this quarter"' onfocus="this.style.color='#000000';handleInput(this,'focus');" onblur="this.style.color=this.value=='' ? '#BCBCBC' : '#000000';handleInput(this,'blur');" autocomplete="off" onkeypress="if (event.keyCode==13) { find_in_relevant_search_in_all(); }" />
          </span>
          <input type="button" value="Find" class="submit" id="submit_search_transcript_in_all" onclick="find_in_relevant_search_in_all();" />
          <div id="word_not_found_message_in_all" class="word_not_found_message" style="display:none;">Text not found.</div>
        </form>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <br>
    <div class="mini_category">
    <div class="compare_to_snippet">
      <div class="sidebar_title_bk">
        <span class="sidebar_title_text">Compare to:</span>
      </div>
      <div class="compare_to_snippet_content">
        <div id="article_transcript_previous_statement_sidebar">
          <ul>
            <li><a href="/symbol/vvus/transcripts">All VVUS Transcripts</a></li>
            <li><a href="/analysis/transcripts/healthcare">Other Companies in this sector</a></li>
        </ul>			
      </div>
    </div>
  </div>
  </div>

   <div id="earning_survey" class="mini_category" style="width:300px; height: 250px;display:none">
    <div class="compare_to_snippet">
      <div class="sidebar_title_bk">
        <span class="sidebar_title_text">EARNINGS CALL FEEDBACK SURVEY</span>
      </div>
      <div id="earning_survey_container">
        <div><b>Vivus, Inc.</b> released its FQ4 2013 Results in their Earnings Call on November 05, 2014.</div>
        <div id="earning_survey_question" class="mt10">Do you feel more positive or less positive about <b>Vivus, Inc.</b> after ready these results?</div>
        <div id="earning_survey_answer">
            <input class="mt10" type="radio" name="morePositive" onclick="nextQuestion(true, this.value)" value="More Positive">More Positive<br>
            <input class="mt10" type="radio" name="lessPositive" onclick="nextQuestion(false, this.value)" value="Less Positive">Less Positive<br>
            </div>
    </div>
      <div id="earnings_survey_email_checkbox" style="display: none" class="mt10"><input id="checkbox_receive_earnings_result" type="checkbox" name="vehicle">I would like to receive survey results<br></div>
    </div>
 </div>

<script>
var receiveResults = 'no';
var questionNumber = 1;
var symbolName = 'Vivus, Inc.';
var container = $('earning_survey_container');
Mone.event('tr_survey','first_q','shown');

function getTextBoxContent(){
  return $("earning_survey_comment").value;
}

function nextQuestion(positiveAnswer, answerContent){
  questionNumber++;
  if($('checkbox_receive_earnings_result').checked){
    receiveResults = 'yes';
  }
    switch(questionNumber){
    case 2:
      if(positiveAnswer){
        firstAnswerWasPositive = true;
        Mone.event('tr_survey','first_q','more_positive',{data:{send_results:receiveResults}});
        transition('<div id="earning_survey_question">Do you currently own <b>' + symbolName + '</b> Company stock?</div>\n\
         <div id="earning_survey_answer"><form action=""><input class="mt10" type="radio" name="yes" onclick="nextQuestion(true, this.value)" value="Yes">Yes<br>\n\
        <input class="mt10" type="radio" name="no" onclick="nextQuestion(false, this.value)" value="No">No</form> </div>');
        Mone.event('tr_survey','second_q_more','shown');
      }
      else{
        firstAnswerWasPositive = false;
        Mone.event('tr_survey','first_q','less_positive',{data:{send_results:receiveResults}});
        transition('<div id="earning_survey_question"> What would help you feel more positive about <b>' + symbolName + '</b> Company as an investment opportunity?</div>\n\
               <textarea id="earning_survey_comment" rows="4" cols="38" placeholder="Write here your comment"></textarea>\n\
                <a href="javascript:nextQuestion(false, getTextBoxContent());"><div id="eaning_survey_submit">Submit &raquo;</div></a>');
        Mone.event('tr_survey','second_q_less','shown');
        
      }
      break;

    case 3:
      if(firstAnswerWasPositive){
        if(positiveAnswer){
          Mone.event('tr_survey','second_q_more','yes', {data:{send_results:receiveResults}});
        } 
        else{
          Mone.event('tr_survey','second_q_more','no', {data:{send_results:receiveResults}});
        }
        transition('<div id="earning_survey_question">Are you more or less likely to purchase <b>'+ symbolName + '</b> as a result of reading this transcript?</div>\n\
          <center><form action=""><input class="mt10" type="radio" name="moreLikely" onclick="nextQuestion(true, this.value)" value="More likely to purchase stock">More likely to purchase stock<br>\n\
          <input class="mt10" type="radio" name="lessLikely" onclick="nextQuestion(false, this.value)" value="Less likely to purchase stock">Less likely to purchase stock</form></center>');
          Mone.event('tr_survey','third_q','shown');
        }
      else{
        Mone.event('tr_survey','second_q_less','submited',{data:{answer:answerContent, send_results:receiveResults}});
        thanksMessage();
      }
      break;
      
    case 4:
      if(positiveAnswer)
        Mone.event('tr_survey','third_q','more_likely', {data:{send_results:receiveResults}});
      else
        Mone.event('tr_survey','third_q','less_likely', {data:{send_results:receiveResults}});
      
      thanksMessage();
      break;
  }
  function thanksMessage(){
    transition('<div id="earning_survey_question"></div><div id="earning_survey_comment">Thank you for your response.</div>', true);
  }
}

function transition(newHTML, isTanksMessage){
  Effect.Fade($('earnings_survey_email_checkbox'));
  Effect.Fade(container, { afterFinish:
                  function () {
                    container.update(newHTML);
                    container.appear();
                    if(receiveResults == 'no' && !isTanksMessage && SA.Data.User.email()) $('earnings_survey_email_checkbox').appear();
                    else $('earnings_survey_email_checkbox').fade();
                   // else $('earnings_survey_email_checkbox').appear();

          } } );

}

</script>
  <div class="stickyad_wrapper">
    <div class="item banner300x250" id="transcript_dart_sticky"></div>
  </div>
  <script type="text/javascript">
     SA.Utils.Ads.add({el:$('transcript_dart_sticky'), HadCreated:false, size:'300x250', delta:10, info:'http://ad.doubleclick.net/N6001/adj/sek.earnings/reports;sz=300x251;x=x;tile=4;d=earnings;pos=b;t=reports;aid=2646055;d=sectors;t=transcripts;t=us;t=biotechnology;t=healthcare;t=article;z=1;a=sa-transcripts;cnt=7;cnt=20;cnt=24;cnt=37;cnt=41;pr=vvus;s=vvus;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
     SA.Utils.Ads.run();
  </script>

</div>

<script>
  function find_in_relevant_search_in_this() {
    if ($('search_transcript_in_this').value.trim() == "" || $('search_transcript_in_this').value == 'e.g. "this quarter"') return false;
    ValidFindInTranscript();    
  }
  function find_in_relevant_search_in_all() {
    if ($('search_transcript_in_all').value.trim() == "" || $('search_transcript_in_all').value == 'e.g. "this quarter"') return false;
    FindTermInAllTranscripts($('search_transcript_form_in_all'), 'transcript_page');
  }
</script>
</div>

  </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/1kppj" />
</div>
<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
          <a href="https://play.google.com/store/apps/details?id=com.seekingalpha.webwrapper" target="_blank" onclick="mobile_app_click()" class="google_play_mini_badge"></a>
          <a href="https://itunes.apple.com/us/app/seeking-alpha-portfolio/id552799694?mt=8" target="_blank" onclick="mobile_app_click()" class="app_store_mini_badge"></a>
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
   <a href="https://www.facebook.com/Seekingalpha" class="share_btn fb" sasource="footer" target="_blank"></a>
   <a href="https://twitter.com/SeekingAlpha" class="share_btn twitter" sasource="footer" target="_blank"></a>
   <a href="https://plus.google.com/+seekingalpha" class="share_btn google" rel="publisher" sasource="footer" target="_blank"></a>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/leader-board/opinion-leaders" sasource="footer">Top Authors</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/sitemap" sasource="footer">Sitemap</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2014 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <div class="cleaner"></div>
</div>
<script>
  if (SA.Data.User.loggedIn() && is_pro) {
    setProDashboardUrl($$('a[href="/dashboard/pro"]'));
  }

  function mobile_app_click(){
    var location_pathname = location.pathname.split('/');
    var source = location.pathname.split('/')[1];

    if (source == '')
      source = 'home_page';
    else if (source == 'account' && location_pathname[2] == 'email_preferences')
      source = 'email_preferences';

    Mone.event('app_promo', 'footer_' + source, 'clicked');
  }
</script>
<div id="first_portfolio_unit_ref" style="display: none"> <div>
  <table id="first_portfolio_unit" style="border-top: 1px solid #DDD; padding-bottom: 7px !important; padding-top: 4px;">
    <thead><tr><th class="fs12">Symbol</th><th class="tr fs12">Price</th><th class="tr fs12">% Chg</th><th></th><th class="tc fs12">Remove</th><th></th></thead>
    <tbody>
        <tr id="first_portfolio_unit_cell0" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input0" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price0" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change0" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button0" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell0')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell1" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input1" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price1" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change1" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button1" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell1')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell2" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input2" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price2" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change2" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button2" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell2')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell3" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input3" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price3" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change3" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button3" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell3')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell4" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input4" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price4" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change4" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button4" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell4')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell5" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input5" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price5" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change5" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button5" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell5')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell6" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input6" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price6" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change6" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button6" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell6')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell7" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input7" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price7" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change7" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button7" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell7')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
    </tbody>
  </table>
</div>

<script>SA.Units.Portfolio.First_portfolio_unit.init('first_portfolio_symbol_input',8, 'transcript Register')</script></div>

<script type="text/javascript">
  Event.observe(window, 'scroll', run_article_end_mone);
  if (location.href.match(/part=single/) == null){
  	$('tab_cmd').show();
  	$('pag_cmd').show();
  }


  $('last_page_index').innerHTML = getPartialSlice(1,sliceSize,false,true,true);


  /* Roadblock test */
  function transcript_rb_show(){
     if (readCookie('user_email') && readCookie('user_email').length > 0 && !AlphaBox.isOpen) {
       SA.Utils.Popup.roadblock_login(); return;
     }
     //temporary remove iPad promo
     /*if (SA.Utils.Env.isIPad){
         ipad_roadblock_new();
     }*/
     else {
       if (document.viewport.getDimensions().height > 400){
         title = "Seeking Alpha transcribes 10,000+ earnings calls per year. For full, free access to these transcripts, please register and set up a portfolio in two easy steps:";
         new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
       }
     }
  }
  /* Roadblock test */

  SeekingAlpha.Initializer.onDOMLoad(function(){

    /* Roadblock test */

    SA.Pages.Article.primary = "vvus";
    SA.Pages.Article.init();
    if ($('article_source')) {$('article_source').hide();}

    rb = new roadblock('transcript');
    rb.additional_login_title = " for full transcript access";
    rb.register_show = transcript_rb_show;
    if (readCookie('ivebeenhere') && !readCookie("sessioncfr")) {
      if (!SA.Data.User.loggedIn() && !SA.Pages.Article.from_partner() && location.href.match("page=([0-9]+)") && location.href.match("page=([0-9]+)")[1] > 1 && document.viewport.getDimensions().height > 400) {
        new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
      }
    } else {
        createCookie('ivebeenhere',true);
    }
    if (!SA.Data.User.loggedIn()){
      SA.Pages.Article.hide_features_for_roadblock();
      if ($('tab_single_bottom')) {$('tab_single_bottom').show();}
    }
    /* Roadblock test */
  });

    SeekingAlpha.Initializer.AddAfterLoad(function(){
      SA.Pages.Article.articlePromo({"allSlugs":["vvus"],"primarySlug":"vvus"});
    });
</script>
    

<link href="http://static1.cdn-seekingalpha.com/stylesheets/packaged/footer_packaged.css?1415180553" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  window.jspell_urls = ["http://static.cdn-seekingalpha.com/javascripts/packaged/jspell_packaged.js?1415180514"]
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static.cdn-seekingalpha.com/javascripts/packaged/sa.js");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static2.cdn-seekingalpha.com/javascripts/tops.js?1396435232");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css?t=1415299713')});

  if (SA && SA.Data && SA.Data.User && SA.Data.User.loggedIn() && SA.Data.User.email() && SA.Data.User.email().match(/@seekingalpha.com/)){
    try{$('user_settings_pop').children[0].insert("<li class='mt10'><a href='javascript:void(0)' onclick='switch_status()'>PRO ON / OFF</a></li>");}catch(e){}
  }

  function switch_status(){
    new Ajax.Request('/authentication/get_menu', {
      asynchronous:true,
      method:'get',
      onComplete: function(transport) {
        eval(transport.responseJSON.code);
      }
    });
  }

  try{
    if (!siteon) {
      //temporary disabled until we'll decide on right wording
      //document.body.appendChild(new Element('div', {id: 'outage_message'}).update('Most of Seeking Alpha is currently unavailable due to scheduled maintenance. Most published articles are still available for viewing. We apologize for any inconvenience.'));
      $('user_settings_wrapper').hide();
    }
  } catch(e){}
  PortfolioNotification.run();
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>

<script src="http://static.cdn-seekingalpha.com/javascripts/packaged/footer_packaged.js?1415180511" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
  }
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>


    <div class="cleaner"></div>
  </body>
</html>
